Autolus Therapeutics plc, an early commercial-stage biopharmaceutical company, reported a net product revenue of $74.3 million for the year ended December 31, 2025, stemming from sales of its newly launched product, AUCATZYL, in the United States. This marks a significant shift from the previous fiscal year, where the company recorded no product revenue due to AUCATZYL's FDA approval occurring in November 2024, with the commercial launch following in January 2025. The company's total revenue, including license revenue, reached $75.4 million in 2025, a substantial increase from the $10.1 million reported in 2024, which was primarily driven by license revenue from collaborations.
Despite the revenue surge, Autolus experienced a net loss of $287.5 million in 2025, compared to a net loss of $220.7 million in 2024. This increase in net loss is attributed to a rise in cost of sales to $96.4 million, reflecting the expenses associated with commercial manufacturing, and an increase in selling, general, and administrative expenses to $131.9 million, driven by the expansion of commercial operations and personnel. Research and development expenses, net, decreased to $117.7 million, primarily due to the reallocation of resources to commercial manufacturing and a decrease in U.K. R&D tax credits.
Key operational developments included the launch of AUCATZYL in the United Kingdom following NICE recommendation and the presentation of real-world data from the ROCCA Consortium, demonstrating improved safety and efficacy compared to the FELIX clinical trial. The company is also advancing obe-cel in other oncology and autoimmune indications, with ongoing Phase 1/2 trials in pediatric r/r B-ALL and Phase 1 trials in severe refractory systemic lupus erythematosus and progressive multiple sclerosis. These clinical programs are supported by collaborations with UCL and other entities.
Looking ahead, Autolus plans to continue building upon the commercialization of AUCATZYL in the United States and the United Kingdom, optimize manufacturing operations, and develop obe-cel for additional indications. The company's existing cash and cash equivalents of $104.1 million and available-for-sale debt securities of $196.6 million as of December 31, 2025, are projected to fund operations for at least the next twelve months. However, the company acknowledges the need for additional funding to achieve profitability and complete the development and commercialization of its product pipeline, which may involve equity offerings, collaborations, or strategic alliances.
About Autolus Therapeutics plc
Autolus Therapeutics plc is a biopharmaceutical company specializing in next-generation programmed T cell therapies for cancer and autoimmune diseases. Its core product, AUCATZYL (obe-cel), is an autologous CD19-targeting CAR T cell therapy approved for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Autolus develops modular, engineered T cell therapies designed to improve efficacy, safety, and durability, supported by proprietary manufacturing and global commercial capabilities targeting hematological and solid tumor markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.